Table 2.
Outcomes by source of exposure
| Characteristic | Overall cohort (N = 1201) | Community acquired (n = 914) | Nosocomial acquired (n = 287) | P value |
|---|---|---|---|---|
| Recurrence of CDI (n, %) | 270, 22·5% | 193, 21·1% | 77, 26·8% | 0·043 |
| Pre-CDI diagnosis antibiotic continued after CDI diagnosis* (n, %) | 82, 12·2% | 53, 10·6% | 29, 16·6% | 0·042 |
| Hospitalization within 21 days after CDI diagnosis (n, %) | 33, 2·8% | 19, 2·1% | 14, 4·9% | 0·011 |
| Ambulatory CDI treatment (n, %) | 0·041 | |||
| Metronidazole | 1024, 85·3% | 790, 86·4% | 234, 81·5% | |
| Vancomycin | 177, 14·7% | 124, 13·6% | 53, 18·5% | |
| Death within 6 months of CDI diagnosis (n, %) | 109, 9·1% | 33, 3·6% | 76, 26·5% | <0·001 |
| CDI-related death within 6 months of diagnosis (n, %) | 13, 11·9% | 3, 9·1% | 10, 13·2% | 0·751 |
CDI, Clostridium difficile infection.
*
Among patients who received an antibiotic in the 180 days prior to CDI diagnosis date (n = 674).